IceCure Medical (ICCM) Projected to Post Earnings on Wednesday

IceCure Medical (NASDAQ:ICCM) is projected to release its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($1.5167) per share and revenue of $1.45 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 11:00 AM ET.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Tuesday, May 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03). IceCure Medical had a negative net margin of 441.60% and a negative return on equity of 211.73%. The business had revenue of $0.91 million during the quarter, compared to analyst estimates of $1.34 million. On average, analysts expect IceCure Medical to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

IceCure Medical Trading Up 12.6%

NASDAQ ICCM opened at $3.13 on Wednesday. The business’s 50-day moving average price is $4.31 and its 200 day moving average price is $10.65. IceCure Medical has a twelve month low of $2.12 and a twelve month high of $42.00. The company has a market capitalization of $10.74 million, a PE ratio of -0.43 and a beta of 0.47.

Institutional Trading of IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Jane Street Group LLC bought a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned approximately 0.16% of IceCure Medical as of its most recent filing with the Securities and Exchange Commission. 0.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on ICCM shares. Maxim Group dropped their price objective on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Wall Street Zen raised shares of IceCure Medical to a “sell” rating in a research report on Sunday, July 12th. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Friday, July 17th. Finally, Alliance Global Partners assumed coverage on shares of IceCure Medical in a research report on Monday, May 4th. They set a “buy” rating for the company. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, IceCure Medical has an average rating of “Hold” and a consensus price target of $62.70.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.